Teicoplanin is named as an intervention in 2 current clinical trials in our India and Spain registers. None are recruiting at the moment. The most common phase is Not applicable. The sponsor with the most trials is Institute of Liver and Biliary Sciences, India (1). The most-studied condition is Acute-On-Chronic Liver Failure. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
NCT07590648 · ClinicalTrials.gov ↗ · Febrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies
|
Phase 4 | Not yet open | Hospital Universitari Vall d'Hebron Research Institute | Spain |
|
Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.
NCT06818565 · ClinicalTrials.gov ↗ · Acute-On-Chronic Liver Failure
|
Not applicable | Not yet open | Institute of Liver and Biliary Sciences, India | India |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Teicoplanin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
2026-526149-91-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 3 | Authorised | Friedrich-Schiller-Universitaet Jena | Germany |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
9 single-substance products containing Teicoplanin on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Institute of Liver and Biliary Sciences, India | 1 |
| Hospital Universitari Vall d'Hebron Research Institute | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in India | 1 | 0 |
| Clinical trials in Spain | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our India and Spain registers name Teicoplanin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Institute of Liver and Biliary Sciences, India (1) and Hospital Universitari Vall d'Hebron Research Institute (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 9 single-substance products containing Teicoplanin, for example Targocid 200mg Powder and Solvent for Solution for Injection/infusion or oral solution (Sanofi-Aventis Ireland Limited T/A SANOFI). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 2 entries for Teicoplanin: 2 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Teicoplanin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Teicoplanin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Teicoplanin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.